

## Supply issues summary w/c 1<sup>st</sup> April 2024

Supply Issue/ Manufacturer	Resupply date	Comment
Acetazolamide (Diamox SR) 250mg modified-release capsules	OOS until 7 <sup>th</sup> June 2024	<ul style="list-style-type: none"> <li>Acetazolamide immediate release 250mg tablets remain available and can support an uplift in demand.</li> </ul>
<b>ADHD medicines</b>	Various updates	<ul style="list-style-type: none"> <li>See the SPS dedicated <a href="#">page</a></li> </ul>
Adrenaline 150/ 300 /500 microgram (Emerade) auto-injectors / Bausch & Lomb UK Ltd	OOS until 16 <sup>th</sup> December 2024	<ul style="list-style-type: none"> <li>There are currently sufficient supplies of Jext and EpiPen Junior to meet normal UK demand for adrenaline 150microgram auto-injectors</li> </ul>
Aprepitant 125mg oral powder sachets	OOS until 16 <sup>th</sup> August 2024	<ul style="list-style-type: none"> <li>The following alternatives remain available: Aprepitant 80mg and 125mg capsules</li> </ul>
Benperidol (Anquil®) 250microgram tablets	OOS until 2 <sup>nd</sup> August 2024	<ul style="list-style-type: none"> <li>Review needed by a relevant mental health specialist</li> </ul>
Bismuth subsalicylate (Pepto-Bismol)	OOS until 30 <sup>th</sup> October 2024	<ul style="list-style-type: none"> <li>Alternative medicines for acid reflux, indigestion, diarrhoea, and nausea remain available.</li> </ul>
Bumetanide 5mg tablets	OOS until 3 <sup>rd</sup> May 2024	<ul style="list-style-type: none"> <li>Bumetanide 1mg tablets remain available and can support increased demand.</li> <li>Bumetanide 1mg/5ml SF oral solution remains available but is unable to support increased demand.</li> </ul>
Buserelin nasal spray (Suprecur ) /Neon Healthcare Ltd	150micrograms OOS until 6 <sup>th</sup> December 2024 5.5mg OOS until 5 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>Alternative parenteral and nasal GnRH analogues</li> </ul>
Capsaicin 0.025% and 0.075% cream	OOS until 6 <sup>th</sup> January 2025	<ul style="list-style-type: none"> <li>Consider if topical therapy still appropriate, unlicensed 0.025% and 0.075% cream available</li> </ul>
Cefalexin 250mg tablets	OOS until 3 <sup>rd</sup> May 2024	<ul style="list-style-type: none"> <li>The following products remain available and can support during this time: <ul style="list-style-type: none"> <li>Cefalexin 250mg capsules</li> <li>Cefalexin 125mg/5ml oral solution</li> <li>Cefalexin 250mg/5ml oral solution</li> </ul> </li> </ul>
Co-trimoxazole 40mg/200mg/5ml oral suspension sugar free	OOS until 15 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>Co-trimoxazole 80mg/400mg/5ml oral suspension remains available and can support increased demand</li> </ul>

		<ul style="list-style-type: none"> <li>Where this is not suitable, unlicensed supplies of co-trimoxazole 40mg/200mg/5ml oral suspension sugar free may be sourced, lead times vary</li> </ul>
Creon 25,000 gastro-resistant capsules	OOS until 5 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>Creon 10,000 gastro-resistant capsules remain available and can support a partial increase in demand.</li> <li>Alternative pancreatin preparations remain available, however, are unable to support an increase in demand.</li> </ul>
Cyanocobalamin (Cytamen) 1mg/1ml solution for injection ampoules	Resupply date to be confirmed	<ul style="list-style-type: none"> <li>Clinicians should consider prescribing hydroxocobalamin 1mg/ml injection.</li> <li>If this is unsuitable, advice should be sought from specialists on management options.</li> </ul>
Desmopressin 10micrograms/dose nasal spray	OOS until 5 <sup>th</sup> July 2024	<ul style="list-style-type: none"> <li>Desmopressin 10micrograms/actuation nasal spray remains available from Aspire Pharma Ltd.</li> </ul>
Diazepam 2mg/5ml oral solution sugar free	OOS until 5 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>Diazepam tablets remain available.</li> <li>Unlicensed diazepam 2mg/5ml oral suspension (sugar free) 'Specials' can be sourced.</li> </ul>
Diazepam 10mg/2.5ml rectal solution tubes	OOS until 3 <sup>rd</sup> May 2024	<ul style="list-style-type: none"> <li>Review patients and consider prescribing midazolam oromucosal solution as appropriate, ensuring that the patient is not intolerant to any of the excipients and the parent/carer is counselled on the appropriate dose and volume required, and how to administer the dose</li> <li>Where midazolam oromucosal solution is not appropriate, consider prescribing diazepam 5mg/2.5ml rectal solution tubes to make up the dose required for the patient, ensuring that the parent or carer is aware of how to do this and reminded of the need to repeat this process for any subsequent doses</li> </ul>
Dicycloverine 10mg/5ml oral solution	OOS until 31 <sup>st</sup> July 2024	<ul style="list-style-type: none"> <li>If patients are able to swallow solid dosage forms and consider prescribing dicycloverine 10mg tablets if appropriate; and</li> </ul>

		<ul style="list-style-type: none"> <li>Consider prescribing a liquid formation of an alternative antispasmodic for patients unable to swallow solid dosage forms</li> </ul>
Dioralyte oral rehydration sachets	Resupply date to be confirmed	<ul style="list-style-type: none"> <li>Consider the use of alternative oral rehydration treatments where stocks of Dioralyte and Dioralyte Relief are unavailable</li> </ul>
Epilim (sodium valproate) syrup 200mg/5ml	OOS until 26 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>Epilim 200mg/5ml liquid (sugar-free) remains available and can support increased demand.</li> </ul>
FemSeven Sequi transdermal patches	OOS until 3 <sup>rd</sup> January 2025	<ul style="list-style-type: none"> <li>Specialist importers can source unlicensed products.</li> </ul>
Fiasp FlexTouch (insulin aspart) 100units/ml solution for injection 3ml pre-filled pens	OOS until 3 <sup>rd</sup> January 2025	<ul style="list-style-type: none"> <li>Fiasp Penfill (insulin aspart) 100units/ml solution for injection 3ml cartridges remain available and can support increased demand.</li> </ul>
Fluoxetine (Olena) 20mg dispersible tablets	OOS until 31 <sup>st</sup> May 2024	<ul style="list-style-type: none"> <li>The following alternatives are available: <ul style="list-style-type: none"> <li>Capsules, including the 10mg and 20mg strengths.</li> <li>Citalopram 40mg/mL oral drops and escitalopram (Cipralext) 20mg/mL oral drops.</li> </ul> </li> </ul>
GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, exenatide)	OOS until 27 <sup>th</sup> December 2024	<ul style="list-style-type: none"> <li>Very limited, intermittent supplies of all GLP-1 Ras – see <a href="#">SPS</a> website.</li> <li>Limited supply will only be available for existing diabetic patients</li> </ul>
Griseofulvin 125mg and 500mg tablets	OOS until 19 <sup>th</sup> April 2024.	<ul style="list-style-type: none"> <li>Alternative oral antifungals remain available.</li> <li>The following specialist importers have confirmed they can source unlicensed griseofulvin 125mg and 500mg tablets (please note there may be other companies that can also source supplies): <ul style="list-style-type: none"> <li>Alium Medical</li> <li>Target Healthcare</li> </ul> </li> </ul>
H2-antagonists/ Various brands	Various updates	<ul style="list-style-type: none"> <li>Please refer to the local <a href="#">Ranitidine Switch Protocol</a> for use in primary care.</li> <li>See <a href="#">here</a> for updates on resupply dates.</li> </ul>
HRT	Various updates – largely in stock	<ul style="list-style-type: none"> <li>See <a href="#">BMS</a> or <a href="#">SPS</a> for current availability</li> </ul>

hydrocortisone 0.1% cream (Marlborough Pharmaceuticals Ltd)	0.1% OOS until 5 <sup>th</sup> July 2024	<ul style="list-style-type: none"> <li>• The Dermacort SmPC states that clinical studies have confirmed that 0.1% Dermacort is equivalent to 1.0% hydrocortisone cream BP/BPC.</li> <li>• Both 0.1% and 1.0% hydrocortisone are classed as mildly potent topical corticosteroids. Potency of a topical corticosteroid preparation is a result of the formulation as well as the corticosteroid.</li> </ul>
Hydrocortisone 2.5mg muco-adhesive buccal tablets sugar free / Accord Healthcare Ltd	OOS until 1 <sup>st</sup> June 2024	<ul style="list-style-type: none"> <li>• Other over-the-counter preparations such as topical anesthetics, topical analgesics/anti-inflammatory agents and topical antimicrobial agents marketed as oral gels, mouthwashes and oral sprays remain available.</li> <li>• Betamethasone soluble tablets for off-label topical use in the treatment of aphthous ulcers remain available.</li> </ul>
Hyoscine hydrobromide (Scopoderm) 1.5mg patches	OOS until 3 <sup>rd</sup> January 2025	<ul style="list-style-type: none"> <li>• Consider other hyoscine hydrobromide formulations or unlicensed hyoscine hydrobromide (Scopoderm) 1.5mg patches if alternative options are not suitable</li> </ul>
Indometacin (Indocid) 100mg suppositories	OOS until 3 <sup>rd</sup> May 2024	<ul style="list-style-type: none"> <li>• Parallel imports limited supplies of are available.</li> </ul>
Isosorbide mononitrate (Monomil XL) 60mg modified-release tablets	OOS until 28 <sup>th</sup> June 2024	<ul style="list-style-type: none"> <li>• Chemydur 60XL, Isotard 60XL, Relosorb XL 60mg, Monomax XL 60mg, Monosorb XL 60 and Tardisc XL 60 tablets remain available and can all partially support the increased demand.</li> <li>• Other brands of isosorbide mononitrate 60mg modified release-tablets are available but are not able to support the increase in demand.</li> <li>• A Serious Shortage Protocol (SSP) was issued on 26/03/2024.</li> </ul>
Ketotifen 1mg/5ml oral solution sugar free	OOS until 15 <sup>th</sup> March 2024	<ul style="list-style-type: none"> <li>• Prescribing ketotifen 1mg tablets ensuring that the patient is not intolerant to any of the excipients and</li> </ul>

		<p>is counselled on the appropriate dose; and</p> <ul style="list-style-type: none"> <li>• Where the above is not suitable, consider prescribing unlicensed products only where licensed alternatives are not appropriate. Prescribers should work with local pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary.</li> </ul>
Lamotrigine 5mg dispersible tablets	<p>(Teva UK Ltd) OOS until 19<sup>th</sup> April 2024</p> <p>(GlaxoSmithKline UK Ltd) OOS until 5<sup>th</sup> April 2024</p>	<ul style="list-style-type: none"> <li>• Lamictal 2mg and 5mg dispersible tablets remain available but cannot fully support the gap in the market</li> <li>• A number of Specials manufacturers are able to produce unlicensed 5mg/5ml and 25mg/5ml oral suspension (including sugar-free formulations)</li> <li>• Where the above options are not suitable, unlicensed supplies of Lamictal 5mg dispersible tablets may be sourced, lead times vary.</li> </ul>
Lamotrigine tablets (Accord-UK Ltd)	OOS until 30 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>• Alternative generic and branded lamotrigine tablets of all strengths remain available and can support the increased demand.</li> </ul>
Levomepromazine 25mg (Morningside Healthcare Ltd)	OOS until 26 <sup>th</sup> April 2024.	<ul style="list-style-type: none"> <li>• Nozinan 25mg tablets remain available from Neuraxpharm UK Limited and are able to fully support demand. Stock is available via Phoenix and Alliance Healthcare.</li> <li>• Levoro) 5mg/ml oral solution remains available from Galvany Pharma Limited and are able to support with covering demand. Retail/community pharmacies can order from Alliance Healthcare.</li> </ul>
Lidocaine 1% and 2% with adrenaline 100micrograms/20ml / Aspen Pharma Trading Ltd	OOS until 4 <sup>th</sup> October 2024	<ul style="list-style-type: none"> <li>• Alternative local anaesthetic with adrenaline products is available, but care needed with dose of adrenaline</li> </ul>
Medroxyprogesterone 200mg tablets	OOS until 5 <sup>th</sup> April 2024.	<ul style="list-style-type: none"> <li>• Medroxyprogesterone (Provera) 100mg tablets remain available and can support an uplift in demand</li> </ul>
Menadiol 10mg tablets	OOS until 16 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>• Phytomenadione 2mg/0.2ml solution for injection ampoules remain</li> </ul>

		<p>available and can support a limited increase in demand.</p> <ul style="list-style-type: none"> <li>Phytomenadione 10mg/1ml solution for injection ampoules remain available but cannot support an increase in demand.</li> </ul>
Methadone 5mg tablets	OOS until 31 <sup>st</sup> May 2024	<ul style="list-style-type: none"> <li>consider: prescribing methadone 1mg/ml oral solution;</li> <li>prescribing unlicensed products only where licensed alternatives are not appropriate. Prescribers should work with local pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary (see supporting information); or</li> </ul>
Midazolam (Epistatus) 2.5mg/0.25ml and 10mg/1ml oromucosal solution pre-filled oral syringes	2.5mg /0.25ml OOS until 7 <sup>th</sup> June 2024. 10mg/1ml OOS until 15 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>Consider prescribing midazolam (Buccolam or the generic) 2.5mg/0.5ml or Buccolam 10mg/2ml oromucosal solution pre-filled oral syringes where appropriate.</li> </ul>
Minocycline 100mg tablets	OOS until 6 <sup>th</sup> December 2024	<ul style="list-style-type: none"> <li>Clinicians should review patients for inappropriate prescribing of minocycline and consider prescribing alternative tetracyclines such as doxycycline and lymecycline.</li> <li>If the above option is not appropriate, consider prescribing minocycline 100mg modified release capsule (which is available to support increased demand from mid-May 2024) or unlicensed minocycline 100mg tablets.</li> </ul>
Olanzapine (Zypadhera) 210mg, 300mg and 405mg powder and solvent for prolonged release suspension for injection vials	OOS until 22 <sup>nd</sup> March 2024	<ul style="list-style-type: none"> <li>Review current stockholding of Zypadhera 210 mg, 300mg and 405mg powder and solvent for prolonged release suspension for injection. Only order more where current supplies are insufficient for patients scheduled to have a dose before early February 2024 to ensure the maximum number of patients can receive treatment during this time;</li> <li>Use an alternative strength of Zypadhera injection (if available) to administer the prescribed dose if the appropriate strength is not available</li> </ul>

Ophthalmic preparations	Various updates	<ul style="list-style-type: none"> <li>• See <a href="#">here</a> for updates on resupply dates.</li> </ul>
Oral contraceptive tablets	Various updates when applicable	<ul style="list-style-type: none"> <li>• See <a href="#">here</a> for more information.</li> </ul>
Oxcarbazepine 600mg tablets (Viatrix)	OOS until 28 <sup>th</sup> June 2024	<ul style="list-style-type: none"> <li>• Oxcarbazepine 600mg tablets (Morningside) remain available and can support the increased demand.</li> </ul>
Oxybutynin 5mg modified-release tablets	OOS until 12 <sup>th</sup> July 2023	<ul style="list-style-type: none"> <li>• Review patients to determine if this is still the most suitable therapy. Where appropriate, consider switching to (or re-trialling) immediate release oxybutynin tablets or oral solution, at the same total daily dose, but administered in divided doses – dose re-titration may be needed, based on symptoms and tolerability or</li> <li>• If above options are not suitable, consider use of another anticholinergic agent</li> </ul>
Paracetamol Suppositories	OOS 125mg until 27 <sup>th</sup> May 2024. 250mg until 3 <sup>rd</sup> June 2024. 60mg OOS until 5 <sup>th</sup> April 2024.	<ul style="list-style-type: none"> <li>• The following Licensed products remain available 120mg, 240mg, 500mg and 1000mg suppositories.</li> <li>• Unlicensed paracetamol suppositories are available from specialist's importers.</li> </ul>
Permethrin 5% cream	OOS until 22 <sup>nd</sup> March 2024	<ul style="list-style-type: none"> <li>• Unlicensed permethrin 5% cream may be sourced.</li> </ul>
Pethidine 50mg tablets	OOS until 5 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>• The following specialist importers have confirmed they can source unlicensed Pethidine 50mg tablets (please note there may be other companies that can also source supplies): <ul style="list-style-type: none"> <li>○ Mawdsley's</li> <li>○ BAP Pharma</li> </ul> </li> </ul>
Phenytoin sodium 100mg capsules (Accord)	OOS until 31 <sup>st</sup> December 2025.	<ul style="list-style-type: none"> <li>• Phenytoin sodium 100mg capsules (Flynn Pharma) remain available and can support an uplift in demand.</li> </ul>
Phosphate Sandoz effervescent tablets	OOS until 12 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>• Consider dietary replacement, with advice from a dietician if required;</li> <li>• Consider prescribing unlicensed sodium acid (dihydrogen) phosphate 1mmol in 1ml oral solution from Specials manufacturers or unlicensed</li> </ul>

		imports of Phosphate Phebra (16.1mmol phosphate) effervescent tablets. Ensure that the patient is not intolerant to any of the excipients and is counselled on the appropriate dose (and volume) required. Prescribers should work with local pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary
Prednisolone 5mg/5ml oral solution unit dose	OOS until 5 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>• Prednisolone 5mg soluble tablets, rounding to the nearest 5mg dose where appropriate; or</li> <li>• prednisolone 1mg/1ml oral suspension (special order).</li> </ul>
Pristinamycin (Pyostacine) 500mg tablets	Resupply date to be confirmed	<ul style="list-style-type: none"> <li>• Pristinamycin, an unlicensed antibiotic medicine, is currently in limited supply with no known date for resolution</li> </ul>
Progesterone (Crinone) 8% vagina gel and Progesterone (Lutigest) 100mg vaginal tablets	OOS until 3 <sup>rd</sup> May 2024	<ul style="list-style-type: none"> <li>• Consider prescribing alternative progesterone products for supplementation</li> </ul>
Rasagiline 1mg tablets	OOS until 5 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>• Rasagiline 1mg tablets are in limited supply with a full resupply date to be confirmed.</li> <li>• Unlicensed supplies of rasagiline 1mg tablets may be sourced, lead times vary.</li> </ul>
Salbutamol 2.5mg/2.5ml and 5mg/2.5ml nebuliser liquid unit dose vials	OOS until 28 <sup>th</sup> June 2024	<ul style="list-style-type: none"> <li>• The supply position of salbutamol 2.5mg/2.5ml and 5mg/2.5ml nebules has improved.</li> <li>• Salbutamol 2.5mg/2.5ml nebules will be in limited supply from mid-April until late June 2024.</li> <li>• Access to licensed salbutamol 2.5mg/2.5ml nebules will be actively monitored and prioritised for primary care and ambulance services who are less able to use unlicensed supplies.</li> </ul>
Senokot 12 Years Plus syrup (containing 7.5mg/5ml sennosides)	OOS until 3 <sup>rd</sup> May 2024	<ul style="list-style-type: none"> <li>• In patients who can swallow solid oral dosage forms, senna 7.5mg tablets are licensed for use in adults and children over 12 years.</li> </ul>

		<ul style="list-style-type: none"> <li>For patients who are unable to swallow a solid dosage form, alternative laxatives formulated as liquids (e.g., sodium picosulfate, dosusate sodium) or powder for oral solution (e.g., macrogol products, sodium picosulfate) are available.</li> </ul>
Strontium ranelate 2g granules sachets sugar free	OOS until 28 <sup>th</sup> March 2025	<ul style="list-style-type: none"> <li>Alternative treatments used in osteoporosis remain available.</li> </ul>
Sytron (sodium feredetate – iron 27.5mg/5ml) oral solution sugar free	OOS until 4 <sup>th</sup> July 2025	<ul style="list-style-type: none"> <li>Consider whether this particular iron salt is preferred, and if deemed necessary, prescribe this product generically (sodium feredetate 27.5mg/5ml oral solution sugar free), considering appropriateness of use as the available products are classified as food supplements (see alternatives below); or</li> <li>Consider prescribing an alternative iron salt in liquid formulation that is classified as a medicinal product, ensuring the patient has no documented intolerance to that salt and counselling them/carer on dose to be administered; and</li> </ul>
Topiramate tablets	OOS until 30 <sup>th</sup> August 2024	<ul style="list-style-type: none"> <li>Other manufacturers remain in stock of topiramate tablets and can support increased demand.</li> </ul>
Triamcinolone hexacetonide 20mg/1ml suspension for injection ampoules	Resupply date to be confirmed	<ul style="list-style-type: none"> <li>Clinicians should consider prescribing an alternative steroid injection during this time.</li> </ul>
Tresiba (insulin degludec) FlexTouch 100units/ml solution for injection 3ml pre-filled pens	OOS until 31 <sup>st</sup> December 2024.	<ul style="list-style-type: none"> <li>Tresiba Penfill (Insulin degludec) 100units/ml solution for injection 3ml cartridges remain available and can support the increased demand.</li> </ul>
Valganciclovir (Valcyte) 250mg/5ml oral solution	OOS until May 2024.	<ul style="list-style-type: none"> <li>Consider prescribing valganciclovir 450mg tablets as a first line option to deliver full doses, where appropriate</li> <li>consider prescribing unlicensed valganciclovir 250mg/5ml oral suspension available from Specials manufacturers or unlicensed imports</li> </ul>

		of valganciclovir 250mg/5ml oral solution during this period
Varenicline (Champix) 0.5mg and 1mg tablets/ Pfizer	Resupply date to be confirmed	<ul style="list-style-type: none"> <li>No smoking cessation products should be prescribed in primary care</li> </ul>
Vokanamet (Canagliflozin 50mg / Metformin 1g tablets)	OOS until 17 <sup>th</sup> May 2024.	<ul style="list-style-type: none"> <li>Use alternative strength combination product when available.</li> <li>When the alternative combination product is not available, individual constituents will need to be prescribed separately</li> </ul>

### Discontinuations

Supply Issue/ Manufacturer	Date	Comment
Barbiturates – Flynn Pharma	1 <sup>st</sup> September 2024	<ul style="list-style-type: none"> <li>avoid abrupt withdrawal;</li> <li>seek advice from local drug dependency services/local mental health services, which may be able to offer guidance on the management of individual patients.</li> </ul>
Co-magaldrox (Maalox and Maalox Plus) oral suspensions sugar free	22 <sup>nd</sup> January 2024	<ul style="list-style-type: none"> <li>Alternative antacids for the treatment of dyspepsia remain available. Consult the BNF for options.</li> </ul>
Ethinylestradiol tablets	date to be confirmed	<ul style="list-style-type: none"> <li>Specialist importers can source unlicensed products. Lead times may vary.</li> </ul>
Exenatide (Byetta) 5microgram/0.02ml and 10microgram/0.04ml solution for injection	31 <sup>st</sup> March 2024	<ul style="list-style-type: none"> <li>Please refer to the National Patient Safety Alert for information and advice on alternatives.</li> </ul>
Hydrogen Peroxide 3%, 6% and 9% solution	24 <sup>th</sup> November 2023	<ul style="list-style-type: none"> <li>The following specialist importers have confirmed they can source unlicensed hydrogen peroxide solution 3% (please note there may be other companies that can also source supplies): Alium</li> </ul>
Hydromorphone (Palladone) capsules		<ul style="list-style-type: none"> <li>1.3mg capsules remain available and can support the gap in the market for the 2.6mg capsules.</li> </ul>

		<ul style="list-style-type: none"> <li>8mg modified-release capsules remain available and can support the gap in the market for the 16mg and 24mg modified-release capsules.</li> </ul>
Insulatard InnoLet (insulin isophane human) 100units/ml suspension for injection 3ml pre-filled disposable devices	31 <sup>st</sup> May 2024	<ul style="list-style-type: none"> <li>Humulin I KwikPens are available and can provide a full uplift in demand.</li> </ul>
Levemir InnoLet (insulin detemir) 100units/ml solution for injection 3ml pre-filled disposable devices	31 <sup>st</sup> May 2024	<ul style="list-style-type: none"> <li>Levemir FlexPens and Levemir Penfill cartridges remain available and can support increased demand</li> </ul>
Lixisenatide (Lyxumia) 20micrograms/0.2ml solution for injection 3ml pre-filled disposable devices	21 <sup>st</sup> Sep 2023	<ul style="list-style-type: none"> <li>Proactively identify and review patients established on lixisenatide (Lyxumia)</li> <li>Review the need for a glucagon-like peptide receptor agonists (GLP-1 RA) and stop treatment if the patient has not achieved beneficial metabolic effect as set out in NICE NG28</li> </ul>
Mizolastine 10mg modified-release tablets	26 <sup>th</sup> April 2024	<ul style="list-style-type: none"> <li>Alternative non-sedating antihistamines remain available.</li> </ul>
Norditropin (somatropin) NordiFlex 5mg/1.5ml, 10mg/1.5ml and 15mg/1.5ml solution	26 <sup>th</sup> February 2024	<ul style="list-style-type: none"> <li>Proactively identify all patients on these products and refer them to their specialist prescribing centre for review and switching to Omnitrope</li> </ul>
Pancrease HL gastro-resistant capsules	10 <sup>th</sup> November 2023	<ul style="list-style-type: none"> <li>Alternative high strength pancreatin preparations remain available and will be able to support increased demand.</li> </ul>
Sulindac tablets	31 <sup>st</sup> December 2023	<ul style="list-style-type: none"> <li>An alternative NSAID should be prescribed</li> </ul>
Testosterone 50mg/5g transdermal gel unit dose tube	29 <sup>th</sup> December 2023	<ul style="list-style-type: none"> <li>consider prescribing an alternative testosterone gel, ensuring that the patient is not intolerant to any of the excipients and is counselled on</li> </ul>

		the appropriate dose and how to administer it
--	--	---